ACXP Stock Overview
A clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Acurx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.55 |
| 52 Week High | US$8.82 |
| 52 Week Low | US$1.17 |
| Beta | -1.78 |
| 1 Month Change | 28.79% |
| 3 Month Change | -18.53% |
| 1 Year Change | -14.43% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.68% |
Recent News & Updates
Recent updates
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Jan 22Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Oct 30
Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?
Jul 15Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?
Mar 04Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Nov 16Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering
Jul 25Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
May 13Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Jan 22Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth
Sep 30New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
Aug 27Shareholder Returns
| ACXP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.3% | 0.7% | 1.2% |
| 1Y | -14.4% | 5.0% | 27.7% |
Return vs Industry: ACXP underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: ACXP underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ACXP volatility | |
|---|---|
| ACXP Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ACXP's share price has been volatile over the past 3 months.
Volatility Over Time: ACXP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | Dave Luci | www.acurxpharma.com |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.
Acurx Pharmaceuticals, Inc. Fundamentals Summary
| ACXP fundamental statistics | |
|---|---|
| Market cap | US$44.15m |
| Earnings (TTM) | -US$16.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs ACXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACXP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.05m |
| Earnings | -US$16.05m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACXP perform over the long term?
See historical performance and comparison